89bio Inc. (ETNB)
8.03
-0.93 (-10.38%)
At close: Mar 28, 2025, 3:58 PM
8.00
-0.37%
After-hours: Mar 28, 2025, 04:58 PM EDT
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
89bio Inc.
| Country | United States |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street San Francisco, California United States | |
| Website | https://www.89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer & Director |
| Francis W. Sarena | Chief Operating Officer |
| Ryan Stephen Martins | Chief Financial Officer |
| Amanda Kurihara | Vice President of People & Culture |
| Annie J. Chang M.B.A. | Vice President of Investor Relations & Corporate Communications |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Michael Baldwin | Senior Vice President & Head of Quality |
| Quoc Le-Nguyen | Chief Technical Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 4 | Filing |
| Feb 19, 2025 | 4 | Filing |
| Feb 19, 2025 | 4 | Filing |
| Feb 19, 2025 | 4 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |